Rick Doblin at the 2023 Psychedelic Science conference in Denver (Courtesy of Psychedelic Science and MAPS)
September 17, 2024 10:00 AM EDT
People
In Focus

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Max Bayer

Pharma Reporter

In ear­ly 2023, the founder of the psy­che­del­ic med­i­cine com­pa­ny Lykos Ther­a­peu­tics met with a po­ten­tial in­vestor for din­ner, feel­ing out the chem­istry for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times